Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus
Search results for: treat-to-target
Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
Experts question how to apply the new American College of Cardiology and American Heart Association guidelines in patients with rheumatic disease and call for further validation of the risk assessment algorithm
Treat-to-Target Decisions and Dilemmas
A better understanding of targets can lead to better outcomes down the road
Optimizing DMARD Use in Older Adults with Rheumatoid Arthritis
SAN DIEGO—Older adults with rheumatoid arthritis (RA) comprise two groups: those who have lived with diagnosed RA since an early age (young-onset RA) and those who have new-onset RA diagnosed at an older age (≥65 years), known as late-onset RA or, formerly, as elderly onset RA.1 Individuals with late-onset RA have more acute and systemic…
The Physical Exam Begins with a Handshake
During the height of the pandemic four years ago, I took every precaution to avoid, or at the very least, delay contracting COVID-19. I religiously wore a mask in all public settings, I washed my hands so frequently that my skin became dry and cracked, and I studiously maintained a six-foot distance from others. But…
Study: Most Patients with PMR Aren’t Getting Steroid-Sparing Agents in First 2 Years
A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…
Management Updates for a Spectrum of Systemic Autoinflammatory Diseases
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
From Basic Science to Clinical Treatments: An Update on PsA
Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
Non-Radiographic Axial Spondyloarthritis: A Review
SAN DIEGO—Alexis Ogdie-Beatty, MD, MSCE, associate professor of medicine, associate professor of epidemiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, gave a presentation on non-radiographic axial spondyloarthritis (nr-axSpA) in the Review Course prior to ACR Convergence 2023.
Concerning the Back: Updates in AS & nr-axSpA
During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 16
- Next Page »